View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 1, 2014

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

US-based Johnson & Johnson has signed an agreement to acquire a privately held clinical stage biopharmaceutical company, Alios BioPharma, for $1.75bn in cash.

JandJ

US-based Johnson & Johnson has signed an agreement to acquire a privately held clinical stage biopharmaceutical company, Alios BioPharma , for $1.75bn in cash.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

Based in California, US, Alios develops therapies for the treatment of viral diseases.

The discovery and development platform of Alios include chemical library of nucleoside analogues, as well as virology-based screening systems.

Janssen Pharmaceutical Companies of Johnson & Johnson research and development global head William Hait said: "We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major paediatric diseases with no available preventive therapy.

"AL-8176 complements our existing early stage portfolio for RSV, which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five."

"As part of the deal, Johnson & Johnson will acquire Alios ‘s therapeutics portfolio, including the compound AL-8176."

As part of the deal, Johnson & Johnson will acquire Alios ‘s therapeutics portfolio, including the compound AL-8176.

Currently, Alios is carrying out Phase II trials for AL-8176, to treat infants with respiratory syncytial virus (RSV).

The company is developing therapeutics for viral infections, which are caused by respiratory syncytial virus, influenza, rhinovirus, coronavirus and HCV.

Alios BioPharma president and CEO Lawrence Blatt said: "We are so pleased to be joining the Janssen Pharmaceutical Companies of Johnson & Johnson, who have an impressive track record of bringing breakthrough drugs for viral diseases to market."

The deal is expected to be completed in the fourth quarter of this year, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.


Image: Johnson & Johnson headquarters in New Brunswick, New Jersey. Photo: courtesy of Nikopoley.

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology